Limoges Cedex 1

• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting
  2023-503886-44-00 5 2024-06-10 Patients with a histological diagnosis of p53abn HREC, treated with cu
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• The PENTO protocol in Medication-Related Osteonecrosis of the Jaw (MRONJ) Recruiting
  2024-518688-36-00 4 2024-02-29 medication-related osteonecrosis of the Jaw
• ERASE PH-COPD Recruiting
  2022-500862-93-00 5 2024-02-01 Pulmonary Hypertension
• A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I … Recruiting
  2024-514101-65-00 4 2023-12-21 Multiple Myeloma
• For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment … Recruiting
  2023-505420-62-00 5 2023-11-09 Multiple sclerosis
• INduction in Sensitized kidney Transplant recipients without pre-Existing donor-specific AntiboDies: a randomized multicentre trial between … Recruiting
  2022-502007-30-00 5 2023-11-07 Kidney transplant
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul … Recruiting
  2022-502019-12-00 5 2023-09-14 acute myeloid leukemia
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting
  2024-514636-25-00 4 2023-05-04 Stage IIa/IIb < 3 cm seminoma
• Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting
  2023-507778-42-00 4 2023-03-08 Non-Small Cell Lung Cancer II, III
• Phase 2/3 Adaptive Study of VX-147 in Adults and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease Recruiting
  2024-515633-15-00 10 2022-10-25 APOL1-mediated Proteinuric Kidney Disease (AMKD)
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• Study evaluating the interest of imatinib treatment maintenance or interruption after at least 10 years of treatment in patients with locall … Recruiting
  2024-512631-77-00 4 2021-12-20 locally advanced or metastatic Gastrointestinal Stromal Tumors
• RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Recruiting
  2024-514025-30-00 4 2021-03-25 Ocular conservative treatment for retinoblastoma
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri … Recruiting
  2024-516649-38-00 5 2020-12-01 Recurrent ovarian, fallopian tube or primary peritoneal cancer
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel … Recruiting
  2023-507885-21-00 4 2020-08-18 Chronic Inflammatory Demyelinating Polyneuropathy

Showing 73–96 of 190 trials